Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing-Reference-Cited by-同舟云学术

Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing

Published:2018-07-20 Issue:9 Volume:67 Page:1437-1447
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Trabbic Kevin R.,Kleski Kristopher A.,Shi Mengchao,Bourgault Jean-Paul,Prendergast Jillian M.,Dransfield Daniel T.,Andreana Peter R.^ORCID

Funder

National Cancer Institute

U.S. Department of Health and Human Services

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2206-0/fulltext.html

Reference46 articles.

1. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323–5337. https://doi.org/10.1158/1078-0432.ccr-09-0737

2. O’Cearbhaill RE, Ragupathi G, Zhu J, Wan Q, Mironov S, Yang G, Spassova MK, Iasonos A, Kravetz S, Ouerfelli O, Spriggs DR, Danishefsky SJ, Sabbatini PJ (2016) A phase I study of unimolecular pentavalent (Globo-H-GM2-STn-TF-Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers (Basel). https://doi.org/10.3390/cancers8040046

3. Laubreton D, Bay S, Sedlik C, Artaud C, Ganneau C, Deriaud E, Viel S, Puaux AL, Amigorena S, Gerard C, Lo-Man R, Leclerc C (2016) The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity. Cancer Immunol Immunother 65(3):315–325. https://doi.org/10.1007/s00262-016-1802-0

4. Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee SD, Dekaban GA, Fink C, Foster PJ, Gaudet J, Gariepy J, Sekaly RP, Lacombe L, Fradet Y, Foley R (2016) Tn-MUC1 DC vaccination of rhesus macaques and a phase I/II trial in patients with nonmetastatic castrate-resistant prostate cancer. Cancer Immunol Res 4(10):881–892. https://doi.org/10.1158/2326-6066.cir-15-0189

5. Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, Bornmann WG, Spassova M, Bencsath KP, Panageas KS, Chin J, Hudis CA, Norton L, Houghton AN, Livingston PO, Danishefsky SJ (2001) Immunization of metastatic breast cancer patients with a fully synthetic Globo H conjugate: a phase I trial. Proc Natl Acad Sci USA 98(6):3270–3275. https://doi.org/10.1073/pnas.051626298

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies;Frontiers in Immunology;2023-10-03

2. Carbohydrate‐Specific Monoclonal Antibody Therapeutics;Carbohydrate‐Based Therapeutics;2023-09-05

3. A synthetic Tn-BSA conjugate vaccine bearing chitotriose as built-in adjuvant;Carbohydrate Research;2023-08

4. Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors;Cancers;2023-07-08

5. Structural basis of a high-affinity antibody binding to glycoprotein region with consecutive glycosylation sites;2022-07-24